Welcome to the KLK2-PASenger Study
A study for people with hormone resistant prostate cancer
that has spread to other parts of the body (metastasized).
Welcome to the KLK2-PASenger Study
A study for people with hormone resistant prostate cancer
that has spread to other parts of the body (metastasized).
-1400x1386.jpg)
To qualify for the study, you will go through a screening process that may include questions about your medical history, blood tests, a CT or MRI, bone scan, and a physical exam. Check out the criteria below to see if you might be a candidate.
You or your loved one can join the study if:
- You are 18 years of age or older
- You have been diagnosed with hormone-resistant prostate cancer that has spread to other parts of your body (metastasized), but not to the brain
- You have been treated with at least 1 oral hormone therapy but no more than 2 different oral hormone therapies (abiraterone, enzalutamide, apalutamide, and darolutamide)
There are other requirements to participate. The clinical staff will give you more information.
You or your loved one cannot join the study if:
- You have had a solid organ or bone marrow transplant
- You have an autoimmune disease (where your immune system attacks your body) and are taking medications to suppress your immune system
- You have another cancer, other than prostate cancer, that might interfere with the study results
- You’ve had serious heart or stroke problems in the last 6 months
There are other requirements to participate. The clinical staff will give you more information.
The study includes 3 periods: Screening, Treatment, and Follow-up
Screening Period: During the Screening period, you will have tests and procedures, including imaging/scans, to see if you qualify for the study. The study doctor will answer any questions you may have and ask you to sign an Informed Consent Form (ICF) before any study-related procedures.
Treatment Period: If you qualify, you will be randomly assigned to get either the investigational medication with chemotherapy or chemotherapy alone. Both are given by IV infusion over 30 to 60 minutes. This is an open-label study, meaning that you and the clinical staff will know if you are receiving the investigational medication with chemotherapy or chemotherapy alone.
The study schedule is broken out into groups of weeks that repeat, called cycles. All cycles are 6 weeks, except for Cycle 1 (8 weeks) for patients receiving the investigational medication with chemotherapy.*
Follow-up Period: The Follow-up period starts after the end-of-treatment visit and is broken into two parts – post-treatment follow-up and survival follow-up. Your study doctor will let you know when your treatment period ends, and when your end-of-treatment visit will be. Follow-up visits are every 6-12 weeks and may be done at the clinic or on the phone, depending on the phase of follow-up. Follow-up visits help us collect useful long-term information about these treatments on you and your disease.
Click the Download button to find out more information.
Clinical research studies may help to find better ways to treat different conditions. When people from all backgrounds participate in clinical research, it helps us understand how medicines affect people around the world who are impacted by certain conditions and diseases. Your participation may help shape the future of cancer care.
See if you may qualify
Answer the following questions to see if you or someone you know may be eligible to take part in this study.
Please keep in mind: Even if you believe you meet the eligibility criteria, joining a clinical research study is not guaranteed. Whether you’re referred or able to take part depends on a review by a qualified healthcare professional. This questionnaire is intended for United States participants only.
Note about privacy: Email responses may not be encrypted. This means there’s a chance the messages could be seen by someone other than the intended recipient. We will avoid including sensitive personal information in emails whenever possible. However, we cannot guarantee that no sensitive information will be revealed indirectly.
About your information:
With your consent, we will use your answers to help determine whether you may be eligible for this clinical trial. You can withdraw your consent at any time.
Your information may be transferred to countries outside your country of residence, including the United States, which may have different data protection rules.
If you submit any personal information about someone else, you confirm that you have permission to do so.
Please read our Privacy policy for more details.